Literature DB >> 17894274

An overview of FDA medical device regulation as it relates to deep brain stimulation devices.

Carlos Peña1, Kristen Bowsher, Ann Costello, Robert De Luca, Sara Doll, Khan Li, Marie Schroeder, Theodore Stevens.   

Abstract

The United States Food and Drug Administration (FDA) is charged with assuring the safety and effectiveness of a variety of medical products and the FDA's Center for Devices and Radiological Health is responsible for premarket and postmarket regulation of medical devices. In this paper, we review--from device classification and clinical studies to the final marketing application--FDA's premarket requirements and postmarket requirements as they relate to deep brain stimulation devices.

Mesh:

Year:  2007        PMID: 17894274     DOI: 10.1109/TNSRE.2007.903973

Source DB:  PubMed          Journal:  IEEE Trans Neural Syst Rehabil Eng        ISSN: 1534-4320            Impact factor:   3.802


  6 in total

1.  Challenges to deep brain stimulation: a pragmatic response to ethical, fiscal, and regulatory concerns.

Authors:  Joseph J Fins; Gary S Dorfman; Joseph J Pancrazio
Journal:  Ann N Y Acad Sci       Date:  2012-07-23       Impact factor: 5.691

2.  Barriers to investigator-initiated deep brain stimulation and device research.

Authors:  Michael L Kelly; Donald Malone; Michael S Okun; Joan Booth; Andre G Machado
Journal:  Neurology       Date:  2014-03-26       Impact factor: 9.910

3.  Should DBS for Psychiatric Disorders be Considered a Form of Psychosurgery? Ethical and Legal Considerations.

Authors:  Devan Stahl; Laura Cabrera; Tyler Gibb
Journal:  Sci Eng Ethics       Date:  2017-06-26       Impact factor: 3.525

4.  In vivo effects of L1 coating on inflammation and neuronal health at the electrode-tissue interface in rat spinal cord and dorsal root ganglion.

Authors:  C L Kolarcik; D Bourbeau; E Azemi; E Rost; L Zhang; C F Lagenaur; D J Weber; X T Cui
Journal:  Acta Biomater       Date:  2012-06-29       Impact factor: 8.947

Review 5.  Neural interface technology for rehabilitation: exploiting and promoting neuroplasticity.

Authors:  Wei Wang; Jennifer L Collinger; Monica A Perez; Elizabeth C Tyler-Kabara; Leonardo G Cohen; Niels Birbaumer; Steven W Brose; Andrew B Schwartz; Michael L Boninger; Douglas J Weber
Journal:  Phys Med Rehabil Clin N Am       Date:  2010-02       Impact factor: 1.784

6.  Results availability for analgesic device, complex regional pain syndrome, and post-stroke pain trials: comparing the RReADS, RReACT, and RReMiT databases.

Authors:  Faustine L Dufka; Troels Munch; Robert H Dworkin; Michael C Rowbotham
Journal:  Pain       Date:  2015-01       Impact factor: 7.926

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.